(NASDAQ: INVA) Innoviva's forecast annual revenue growth rate of 6.97% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 104.82%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.65%.
Innoviva's revenue in 2025 is $388,521,000.On average, 7 Wall Street analysts forecast INVA's revenue for 2025 to be $28,959,553,094, with the lowest INVA revenue forecast at $27,532,211,700, and the highest INVA revenue forecast at $30,241,094,817. On average, 7 Wall Street analysts forecast INVA's revenue for 2026 to be $32,318,927,050, with the lowest INVA revenue forecast at $28,671,692,205, and the highest INVA revenue forecast at $35,595,307,346.
In 2027, INVA is forecast to generate $35,557,175,125 in revenue, with the lowest revenue forecast at $30,631,389,320 and the highest revenue forecast at $41,287,476,036.